Germline and somatic mutations in von hippel-lindau disease gene and its significance in the development of kidney cancer

Contributions to Nephrology

Volumn 128, Issue , 1999, Pages 1-10

  Shuin, Taro ^a   Kondo, Keiichi ^b   Ashida, Shingo ^a   Okuda, Heiwa ^a   Yoshida, Minoru ^b   Kanno, Hiroshi ^b   Yao, Masahiro ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LIGASE; PROTEIN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; VHL PROTEIN, HUMAN; VON HIPPEL LINDAU PROTEIN;

GENETIC PREDISPOSITION; GENETICS; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MUTATION; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

CARCINOMA, RENAL CELL; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HIPPEL-LINDAU DISEASE; HUMANS; KIDNEY NEOPLASMS; LIGASES; MUTATION; PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0033258130     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000059976     Document Type: Article

References (33)

1. Maher ER, Yates RW, Harries R, Benjamin C, Harris R, Moore AT, Ferguson-Smith MA: Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990;77:1151-1163.
2. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, Walther MM, Weng Y, Duan DR, Dean M, Glavac D, Richards FM, Crossey PA, Ferguson-Smith MA, Paslier DL, Chumakov I, Cohen D, Chinault C, Maher ER, Linehan VM, Zbar B, Lerman MI: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-1320.
3. Duan DR, Humphrey JS, Chen DY, Weng Y, Sukegawa J, Lee S, Gnarra JR, Linehan WM: Characterization of the VHL tumor suppressor gene product: Localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci USA 1995;92:6459-6463.
4. Lee S, Chen DY, Humphrey JS, Gnarra JR, Linehan WM, Klausner RD: Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci USA 1996;93:1770-1775.
5. Iliopoulos O, Ohh M, Kaelin WG Jr: pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci USA 1998;95:11661-11666.
6. Schoenfeld A, Davidowitz EJ, Burk RD: A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci USA 1998;95:8817-8822.
7. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, Lubensky I, Duan DR, Florence C, Pozzatti R, Walther MM, Bander NH, Grossman HB, Brauch H, Pomer S, Brooks JD, Isaacs WB, Lerman MI, Zbar B, Linehan WM: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
8. Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, Nagashima Y, Kitamura H, Latif F, Zbar B, Lerman MI, Yao M: Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994;54:2852-2855.
9. Kanno H, Kondo K, Ito S, Yamamoto I, Fujii S, Torigoe S, Sakai N, Hosaka M, Shuin T, Yao M: Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 1994;54:4845-4847.
10. Eng C, Crossey PA, Mulligan LM, Healey CS, Houghton C, Prowse A, Chew SL, Dahia PL, O'Riordan JL, Toledo SP, Smith DP, Maher ER, Ponder EAJ: Mutations in the RET protooncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet 1995;32:934-937.
11. Kanno H, Shuin T, Kondo K, Yamamoto I, Ito S, Shinonaga M, Yoshida M, Yao M: Somatic mutations of the von Hippel-Lindau tumor suppressor gene and loss of heterozygosity on chromosome 3p in human glial tumors. Cancer Res 1997;57:1035-1038.
12. Duan DR, Pause A, Burgess WH, Aso T, Chen DY, Garrett KP, Conaway RC, Conaway JW, Linehan WM, Klausner RD: Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995;269:1402-1406.
13. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, Kaelin WG Jr: Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 1998;18:732-741.
14. Tsuchiya H, Iseda T, Hino O: Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product. Cancer Res 1996;56:2881-2885.
15. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP: The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997;17:5629-5639.
16. Pal S, Claffey KP, Dvorak HF, Mukhopadhyay D: The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem 1997;272:27509-27512.
17. Kaelin WG, Iliopoulos O, Lonergan KM, Ohh M: Functions of the von Hippel-Lindau tumour suppressor protein. J Intern Med 1998;243:535-539.
18. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG Jr, Iliopoulos O: The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998;1:959-968.
19. Whaley JM, Naglich J, Gelbert L, Hsia YE, Lamiell JM, Green JS, Collins D, Neumann HPH, Laidlaw J, Li FP, Klein-Szanto AJP, Seizinger BR, Kley N: Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet 1994;55:1092-1102.
20. Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MM, Crossey PA, Richards FM, Cairns P, Affara NA, Ferguson-Smith MA, Buys C, Maher ER: Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994;3:2169-2173.
21. Brauch H, Kishida T, Glavac D, Chen F, Pausch F, Hofler H, Latif F, Lerman MI, Zbar B, Neumann HP: Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: Evidence for a founder effect. Hum Genet 1995;95:551-556.
22. Bailly M, Bain C, Favrot MC, Ozturk M: Somatic mutations of Von Hippel-Lindau (VHL) tumorsuppressor gene in European kidney cancers. Int J Cancer 1995;63:660-664.
23. Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, Crossey PA, Webster AR, Affara NA, Ferguson-Smith MA, Brauch H, Glavac D, Neumann HP, Tisherman S, Mulvihill JJ, Gross DJ, Shuin T, Whaley J, Seizinger B, Kley N, Olschwang S, Boisson C, Richard S, Lips CHM, Linehan WM, Lerman M: Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996;8:348-357.
24. Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F, Lerman MI, Zbar B, Affara NA, Ferguson-Smith MA, et al: Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 1994;3:1303-1308.
25. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G, Green J, Hsia YE, Lamiell J, Li H, Wei MH, Schmidt L, Tory K, Kuzmin I, Stackhouse T, Latif F, Linehan WM, Lerman M, Zbar B: Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations wih phenotype. Hum Mutat 1995;5:66-75.
26. Kanno H, Shuin T, Kondo K, Ito S, Hosaka M, Torigoe S, Fujii S, Tanaka Y, Yamamoto I, Kim I, Yao M: Molecular genetic diagnosis of von Hippel-Lindau disease: Analysis of five Japanese families. Jpn J Cancer Res 1996;87:423-428.
27. Clinical Research Group for VHL in Japan: Germline mutations in the von Hippel-Lindau disease (VHL) gene in Japanese VHL. Hum Mol Genet 1995;4:2233-2237.
28. Suzuki H, Ueda T, Komiya A, Okano T, Isaka S, Shimazaki J, Ito H: Mutational state of von Hippel Lindau and adenomatous polyposis coli genes in renal tumors. Oncology 1997;54:252-257.
29. Stolle C, Glenn G, Zbar B, Humphrey JS, Choyke P, Walther M, Pack S, Hurley K, Andrey C, Klausner R, Linehan WM: Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998;12:417-423.
30. Kishida T, Stackhouse TM, Chen F, Lerman MI, Zbar B: Cellular proteins that bind the von Hippel-Lindau disease gene product: Mapping of binding domains and the effect of missense mutations. Cancer Res 1995;55:4544-4548.
31. Yao M, Kondo K, Yoshida M, Kishida T, Shuin T: Molecular genetics of the kidney cancers: Implication of the VHL tumor suppressor gene; in Niimura M, Otsuka F, Hino O (eds): Gann Monograph on Cancer Research. Japan Scientific Societies Press, Tokyo, 1999, pp 205-214.
32. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, et al: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91:9700-9704.
33. Stebbins CE, Kaelin WG Jr, Pavletich NP: Structures of the VHL-Elongin C-Elongin B complex: Implications for VHL tumor suppressor function. Science 1999;284:455-460.